Next Article in Journal
Pseudomonas aeruginosa Biofilm Formation and Its Control
Previous Article in Journal
Is the Gut Microbiome a Target for Adjuvant Treatment of COVID-19?
Previous Article in Special Issue
The Peptide TAT-I24 with Antiviral Activity against DNA Viruses Binds Double-Stranded DNA with High Affinity
Review

Peptides in COVID-19 Clinical Trials—A Snapshot

Institute of Infection and Immunology, St George’s, University of London, London SW17 0RE, UK
Academic Editor: Vasso Apostolopoulos
Biologics 2021, 1(3), 300-311; https://doi.org/10.3390/biologics1030018
Received: 8 September 2021 / Revised: 7 October 2021 / Accepted: 8 October 2021 / Published: 14 October 2021
(This article belongs to the Special Issue Antiviral Peptides - From Discovery to Translation)
Since the beginning of the COVID-19 pandemic, there has been a strong drive and desire to find effective treatments for and protection against the disease. On the webpage ClinicalTrials.gov, a total of 6505 clinical trials currently (September 2021) investigating various aspects of COVID-19 are registered. Of these, 124 studies involving peptides were identified. These 124 were further evaluated, and 88 trials that used peptides only for routine diagnostics were excluded. The remaining 36 trials were classified into 5 different classes according to their function: immunomodulatory (5 trials), regain homeostasis (10 trials), diagnostics/biomarkers (8 trials), vaccination (9 trials), and antiviral activity (4 trials, all overlap with immunomodulatory activities). In the current review, these 36 trials are briefly described and tabularly summarised. According to the estimated finish date, 14 trials have not yet finished. All of the finished trials are yet to report their results. Seven trials were based in the USA, and Egypt, France, the UK, Turkey, and the Russian Federation conducted three trials each. This review aims to present a snapshot of the current situation of peptides in COVID-19 clinical trials and provides a template to follow up on trials of interest; it does not claim to be a complete overview. View Full-Text
Keywords: COVID-19; SARS-CoV-2; peptide; clinical trial COVID-19; SARS-CoV-2; peptide; clinical trial
Show Figures

Figure 1

MDPI and ACS Style

Hilpert, K. Peptides in COVID-19 Clinical Trials—A Snapshot. Biologics 2021, 1, 300-311. https://doi.org/10.3390/biologics1030018

AMA Style

Hilpert K. Peptides in COVID-19 Clinical Trials—A Snapshot. Biologics. 2021; 1(3):300-311. https://doi.org/10.3390/biologics1030018

Chicago/Turabian Style

Hilpert, Kai. 2021. "Peptides in COVID-19 Clinical Trials—A Snapshot" Biologics 1, no. 3: 300-311. https://doi.org/10.3390/biologics1030018

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop